Novo Nordisk A/S (NVO): $1.51 million was the positive money flow into the stock on Thursday and the up/down ratio of ticks was also in favor of the bulls at 1.51. The value of trades done on upticks was $4.47 million, whereas, trades done on downticks were valued at $2.96 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $1.72 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $1.72 million. Novo Nordisk A/S (NVO) fell $0.04 traded at $55.29, a change of -0.07% over the previous day. The stock is 1.34% for the week.
The stock has recorded a 20-day Moving Average of 4.27% and the 50-Day Moving Average is 2.06%. Shares have dropped -4.62% from its 1 Year high price. On Aug 3, 2015, the shares registered one year high at $60.34 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $54.22 and the 200 Day Moving Average price is recorded at $54.38.
Novo Nordisk A/S (NYSE:NVO): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $55.58 and $55.21 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $55.62. The buying momentum continued till the end and the stock did not give up its gains. It closed at $55.39, notching a gain of 0.11% for the day. The total traded volume was 625,456 . The stock had closed at $55.33 on the previous day.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.